Last Updated: November 9, 2026

Secura Company Profile

« Back to Dashboard

What is the competitive landscape for SECURA

SECURA has two approved drugs.

There are eight US patents protecting SECURA drugs.

Summary for Secura

US Patents:	8
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Secura

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Secura	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-003	Feb 23, 2015		DISCN	Yes	No	8,883,842	⤷ Start Trial				⤷ Start Trial
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	11,312,718	⤷ Start Trial	Y			⤷ Start Trial
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	9,840,505	⤷ Start Trial				⤷ Start Trial
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	8,193,182	⤷ Start Trial		Y		⤷ Start Trial
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	9,216,982	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Secura

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Secura	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-002	Feb 23, 2015	6,552,065	⤷ Start Trial
Secura	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-001	Feb 23, 2015	6,552,065	⤷ Start Trial
Secura	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-003	Feb 23, 2015	6,833,384	⤷ Start Trial
Secura	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-003	Feb 23, 2015	7,067,551	⤷ Start Trial
Secura	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-001	Feb 23, 2015	7,067,551	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for Secura Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Mexico	373584	⤷ Start Trial
China	105102000	⤷ Start Trial
Canada	2914284	⤷ Start Trial
New Zealand	613219	⤷ Start Trial
Mexico	2008015900	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Secura Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2456444	SPC/GB21/069	United Kingdom	⤷ Start Trial	SPC/GB21/069 WAS ADDED TO THE JOURNAL 7041 INCORRECTLY IDENTIFYING THE INCORRECT MAXIMUM EXPIRY DATE ON WHICH THE SPC IS BASED. PLEASE SEE THE UPDATED JOURNAL ENTRY.; APPLICANT: INTELLIKINE, LLC; 10931 NORTH TORREY PINES ROAD, LA JOLLA CA 92037, UNITED STATES OF AMERICA; PRODUCT: DUVELISIB; PRODUCT TYPE: MEDICINAL; AUTHORISED:; EU/1/21/1542/001 21 MAY 2021 (NI); EU/1/21/1542/002 21 MAY 2021 (NI) ; FURTHER MA'S ON IPSUM; ; AUTHORISED EXTENSION:; PATENT NO: EP2456444; TITLE: ADENINE DERIVATIVE AS PI3K INHIBITOR; SPC NO: SPC/GB21/069; DATE GRANTED: 05 APRIL 2024; MAXIMUM PERIOD EXPIRES ON: 14 JULY 2035; CORRECTED DATA
2456444	C20210033 00435	Estonia	⤷ Start Trial	PRODUCT NAME: DUVELISIIB;REG NO/DATE: EU/1/21/1542 21.05.2021
2914296	47/2021	Austria	⤷ Start Trial	PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 (MITTEILUNG) 20210521
2456444	46/2021	Austria	⤷ Start Trial	PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 (MITTEILUNG) 20210521
1318980	SPC/GB15/085	United Kingdom	⤷ Start Trial	PRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/15/1023 20150901
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Secura

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.